[(2R,5R,6S)-5-acetyloxy-6-[(1S,3S,7S,8S,11S,12S,14S,15R,16R)-14-acetyloxy-7,12,16-trimethyl-6-oxo-15-pentacyclo[9.7.0.01,3.03,8.012,16]octadec-4-enyl]-2-methyl-3-methylidene-4-oxoheptyl] 2-chloroacetate | 1256464-89-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: [(2R,5R,6S)-5-acetyloxy-6-[(1S,3S,7S,8S,11S,12S,14S,15R,16R)-14-acetyloxy-7,12,16-trimethyl-6-oxo-15-pentacyclo[9.7.0.01,3.03,8.012,16]octadec-4-enyl]-2-methyl-3-methylidene-4-oxoheptyl] 2-chloroacetate
• CAS: 1256464-89-7
• 化学式: C₃₆H₄₉ClO₈
• 分子量: 645.233
• InChiKey: ZPWYYYTYFXOASN-VGZPERKLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.4
• 重原子数：
  45
• 可旋转键数：
  13
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  113
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  neoboutomellerone 、 氯乙酰氯 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 24.0h， 以14%的产率得到[(2R,5R,6S)-5-acetyloxy-6-[(1S,3S,7S,8S,11S,12S,14S,15R,16R)-14-acetyloxy-7,12,16-trimethyl-6-oxo-15-pentacyclo[9.7.0.01,3.03,8.012,16]octadec-4-enyl]-2-methyl-3-methylidene-4-oxoheptyl] 2-chloroacetate
  参考文献：
  名称：

  NGCYCLOARTANONE DERIVATIVES WITH ANTICANCER ACTIVITY

  摘要：

  本发明涉及以下式（I）的化合物： 或其药学上可接受的盐，以及包括相同的药物组合物和将其用作药物的用途，特别是用于治疗增殖性疾病如癌症。

  公开号：

  US20120077777A1

文献信息

• NGCYCLOARTANONE DERIVATIVES WITH ANTICANCER ACTIVITY
  申请人：Long Christophe

  公开号：US20120077777A1

  公开（公告）日：2012-03-29

  The present invention relates to a compound of following formula (I): or to a pharmaceutically acceptable salt thereof, as well as to pharmaceutical compositions including same and to the use thereof as a drug, in particular for treating a proliferative disease such as cancer.

  本发明涉及以下式（I）的化合物： 或其药学上可接受的盐，以及包括相同的药物组合物和将其用作药物的用途，特别是用于治疗增殖性疾病如癌症。
• DERIVES DES CYCLOARTANONES AVEC ACTIVITE ANTICANCEREUSE
  申请人：Pierre Fabre Médicament

  公开号：EP2432799B1

  公开（公告）日：2014-09-10
• Semisynthetic neoboutomellerone derivatives as ubiquitin-proteasome pathway inhibitors
  作者：Joséphine Beck、Yves Guminski、Christophe Long、Laurence Marcourt、Fadila Derguini、Fabien Plisson、Antonio Grondin、Isabelle Vandenberghe、Stéphane Vispé、Viviane Brel、Yannick Aussagues、Frédéric Ausseil、Paola B. Arimondo、Georges Massiot、François Sautel、Frédéric Cantagrel

  DOI：10.1016/j.bmc.2011.11.066

  日期：2012.1

  The interesting pharmacological properties of neoboutomellerones 1 and 2 were the basis for the assembly of a small library of analogues consisting of natural products isolated from the plant Neoboutonia melleri and of semisynthetic derivatives. As the two enone systems (C23-C24a and C1-C3) and the two hydroxyls groups (C22 and C26) of neoboutomellerones are required for activity, modifications were focused on these functional groups. Biological evaluation by using a cellular assay for proteasome activity provided clues regarding the mechanism of action of these natural products and synthetic derivatives. Certain neoboutomellerone derivatives inhibited the proliferation of human WM-266-4 melanoma tumor cells at submicromolar concentration and warrant evaluation as anticancer agents. (C) 2011 Elsevier Ltd. All rights reserved.